Latest posts tagged with #MMSM on Bluesky
According to results from a recent phase II study, most patients with drug-resistant, true #extramedullary #myeloma responded to dual treatment with #talquetamab plus #teclistamab, with researchers observing a 61% PFS and 74% OS at 12 months: https://ow.ly/q6gI50YpblV #MMsm
#HemeSky #MedSky
IMF Chief Medical Officer Dr. Joseph Mikhael and Dr. Melissa Alsina from Moffitt Cancer Center are going LIVE on March 14 in honor of Myeloma Action Month. RSVP for the free Q&A now at https://www.facebook.com/events/1579804813252696
#MoreThanMyeloma #MyelomaActionMonth #mmsm
#KansasCity: Connect with the myeloma community, build your support network, ask the experts your questions, find support in your community, and for FREE on March 28, 2026! Will we see you there? Save your seat before spots are gone: https://mmsm.link/3Ns8Dox
#mmsm
FDA approves teclistamab plus daratumumab hyaluronidase-fihj (Tec-Dara) for relapsed or refractory multiple myeloma patients who have received at least one prior line of therapy. Learn more: https://mmsm.link/fda-approves-tec-dara
#mmsm
🚨BREAKING🚨: The @fda.gov has approved teclistamab plus subcutaneous daratumumab for relapsed/refractory multiple myeloma after at least 1 prior line of therapy. #mmsm #hematology
www.onclive.com/view/fda-app...
Bring your family, friends, & furry companions for a fun-filled day of community! Together we’ll walk, play, & raise funds for life-changing myeloma research. Register at www.classy.org/event/2026-los-angeles-m... #IMFMiraclesforMyeloma #mmsm #losangeles
Let's make a difference together! Join us in sunny #LosAngeles on March 21 to get moving for a day of family fun, or support online from your home. Register now at www.classy.org/event/2026-los-angeles-m...
#IMFMiraclesforMyeloma #MoreThanMyeloma #mmsm
#Detroit community! If you're affected by #myeloma, join us at our FREE Myeloma Community Workshop on June 27! Learn about myeloma treatment options, get your questions answered by the experts, and so much more. Sign up now before spots are gone: https://mmsm.link/4qz1zVQ
#mmsm
#KansasCity myeloma community, will we see you at our IMF Myeloma Community Workshop on March 28? Join us for expert advice, myeloma education, Q&A sessions with the experts, and more! Save your seat before spots are gone: https://mmsm.link/3Ns8Dox
#mmsm #Missouri
Myeloma community, get your questions ready! Join myeloma expert and IMF Dr. Scientific Advisory Board member Dr. Sagar Lonial for a free live Q&A on March 25. RSVP for the free event at https://www.facebook.com/events/922951070141613/
#MoreThanMyeloma #MyelomaActionMonth #mmsm
Aviation weather for Santa Lucia Air Force Base airport in Mexico area (Mexico) is “SPECI MMSM 231742Z 31004KT 8SM SKC 13/01 A3049 RMK HZY” : See what it means on https://www.bigorre.org/aero/meteo/mmsm/en #santaluciaairforcebaseairport #airport #mexico #mmsm #nlu #metar #aviation […]
@fda.gov grants Priority Review to iberdomide for #RRMM.
• Target: E3 ligase modulator (CELMoD)
• Phase 3 EXCALIBUR results: Improved PFS
• Target action date: May 2026
Insights via @medicalprofref.bsky.social.
Read the review: https://bit.ly/3Olgg0s
#mmsm #MultipleMyeloma #FDA
Myeloma community, we want to see you at our Living Well With Myeloma webinar! Join us online on Tuesday, March 10 to learn about movement for myeloma patients and care partners. Register now at https://mmsm.link/46ZdRPl
#mmsm
#MoreThanMyeloma
March Myeloma Action Month will be here soon! We Are #MoreThanMyeloma. Get your merch today to be prepared for March! Raise awareness, shop now at https://international-myeloma-foundation.myshopify.com/
#MyelomaActionMonth #bloodcancer #mmsm
Following the FDA's draft guidance on MRD end points to support accelerated approvals in multiple myeloma, OncLive spoke with experts to gather their insights what this guidance means for future clinical trials #mmsm #oncology
Sign up and read more: www.onclive.com/view/fda-gui...
In this recent Blood Cancer Discovery article, the authors identified the inhibitor of DNA binding (ID) genes as putative suppressors of multiple #myeloma cell fitness.
▶️ Check it out: Dysregulation of the ID2–TCF3 Axis Supports #MultipleMyeloma Cell Growth buff.ly/ku1k1kl #MMSM
WATCH: Kenneth Jin Chang Lim, MBBS, discusses a study investigating the use of dexamethasone prophylaxis to reduce rates of neurotoxicity in myeloma with high ALC after CAR T-cell therapy. @astct.bsky.social @cibmtr.bsky.social #Tandem26 #hematology #mmsm
www.onclive.com/view/dr-lim-...
What do you bring with you to every conference❓
Check out how experts at #Tandem26 answered. 😂
@astct.bsky.social @cibmtr.bsky.social #mmsm #lymsm #leusm #oncology
#hematology
Watch the whole video here ➡️: www.onclive.com/shorts/hemat...
What are the biggest developments and challenges in CAR T-cell therapy❓
At #Tandem26 we met with experts Kenneth Lim, MBBS, Peter Riedell, MD, and Nathan Denlinger, DO, to hear their insights.
@astct.bsky.social @cibmtr.bsky.social #oncology #mmsm
See video here ➡️: www.onclive.com/shorts/tct-2...
The use of prophylactic dexamethasone did not lower the risk of delayed neurotoxicities in patients with multiple myeloma who received cilta-cel.
Read more on these retrospective data presented at #Tandem2026 #mmsm #oncology www.onclive.com/view/prophyl...
Elevate your practice with the latest breakthroughs in #hematology. Discover cutting-edge data in this collection of On Location video interviews from #ASH25, including new research in #MMsm, #CLL, and more: https://ow.ly/GqII50Y8i2V
Wiley Clinical and Health
#HemeSky #MedSky
#KansasCity: Connect with the myeloma community, build your support network, ask the experts your questions, find support in your community, and for FREE on March 28, 2026! Will we see you there? Save your seat before spots are gone: https://mmsm.link/3Ns8Dox
#mmsm
Dr. Sergio Giralt is kicking off #Tandem26 for @mskcancercenter.bsky.social! Join his session to learn about the latest CAR T cell therapies for #multiplemyeloma.
📍 Feb 4, 9:05 a.m.–9:35 a.m. MST | Room 255 A-G
➡️ https://bit.ly/4rgYf25
@astct.bsky.social @cibmtr.bsky.social #mmsm
Low-dose DOACs substantially lowered the risk of #VTE in patients with newly diagnosed #MultipleMyeloma #MMsm, reducing VTE risk to 0.8% compared with an incidence of 5.6% and a risk of 9.8% in patients given prophylactic heparin and aspirin, respectively: https://ow.ly/oVNX50Y88ye
#HemeSky #OncSky
Rahul Banerjee, MD, FACP, discusses the implications of the FDA’s draft guidance on the use of minimal residual disease as a surrogate end point in clinical trials to support the accelerated approval of agents for the treatment of multiple myeloma #mmsm #oncology www.onclive.com/shorts/impli...
Men are twice as likely as women to have stage III #multiplemyeloma at diagnosis and appear to have a greater #tumor burden than women. Published in @americancancersoc.bsky.social.
https://bit.ly/4jJiDpq
#mmsm
What do AI 🤖 and CAR T-cell therapies look like in clinical practice today❓
We took a trip to University of Chicago Comprehensive Cancer Center and spoke with experts to hear their insights. 🤔
#oncology #lymsm #mmsm
WATCH 👀 here ➡️: onclive.com/shorts/exper...
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma @andrew02114.bsky.social #mmsm www.onclive.com/view/ixazomi...
